Induction of allergic bronchial hyperreactivity in DA-rats despite low-level eosinophilia in airways and lack of specific IgE antibodies Source: Annual Congress 2007 - Mouse models of allergic airway inflammation Year: 2007
The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001
Disruption of CD44 variant 6 abolished bronchial hyperresponsiveness, inflammation and mast cell myositis in a murine model of asthma Source: Eur Respir J 2006; 28: Suppl. 50, 217s Year: 2006
Comparison of anti-IL-9 and anti-IL-5 treatment efficacy in a mouse model of airway eosinophilic inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 482s Year: 2003
CCL6 produced by eosinophils drives allergic airway inflammation in mice Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
MMP-9 deficiency reduces airway inflammation and hyperresponsiveness in a mouse model of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001
Intratracheal instillation of anti-CD103 does not affect allergic airway inflammation in a mouse asthma model Source: Eur Respir J 2005; 26: Suppl. 49, 25s Year: 2005
Deficiency of MMP-19 promotes allergen-induced eosinophil burden and airway responsiveness in mice Source: Annual Congress 2007 - Regulation of allergic airway inflammation in animal models of asthma Year: 2007
Narirutin inhibits airway inflammation in an allergic mouse model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020
Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Relationship between allergen-induced increase of AHR to bradykinin, expression of the proliferation marker Ki-67 and eosinophils in bronchial mucosa of atopic asthmatics Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways Year: 2003
CAT-354, an IL-13-neutralising human monoclonal antibody, inhibits airways hyperresponsiveness and eosinophilia in a cynomolgus monkey model of allergen challenge Source: Eur Respir J 2005; 26: Suppl. 49, 232s Year: 2005
Intratracheal instillation of antigen-specific IgG ameliorated murine bronchial asthma via reduction of antigen presentation of airway dendritic cells Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
Experimental specific immunotherapy with timpol decreases allergic sensitization and airway inflammation in murine model of bronchial asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
The development of an airway hyperresponsiveness (AHR) depends on mast cells following sensitization without adjuvant Source: Annual Congress 2006 - Cellular immunology in asthma pathogenesis Year: 2006